News | Breast Biopsy Systems | May 08, 2018

New Analytics Approach Offers Potential of Reducing Unnecessary Breast Biopsies

Study defines advanced statistical methods that can be used with diagnostic imaging output to downgrade breast mass risk classification

New Analytics Approach Offers Potential of Reducing Unnecessary Breast Biopsies

May 8, 2018 — The American Journal of Roentgenology recently published findings on statistical methods for downgrading the risk classification of breast masses to reduce the need for unnecessary breast biopsies. Clinicians from Seno Medical and medical center collaborators from The University of Texas co-authored the report.1  

"The perceived risk of missing a breast cancer diagnosis with breast imaging studies is much higher than the risk of a false-positive diagnosis, leading to breast imagers recommending a breast biopsy whenever the risk of cancer is greater than 2 percent. Sometimes ancillary diagnostic breast imaging studies are performed to reduce risk to less than 2 percent, but it is difficult to know exactly how much risks are reduced even after a negative ancillary diagnostic imaging examination," said Thomas Stavros, M.D., chief medical officer of Seno Medical and a co-author of the report. "However, the use of the Negative Likelihood Ratio (NLR) along with BI-RADS [Breast Imaging-Reporting and Data System] 4 subcategories can help to reduce the number of false-positives without experiencing excessive negative results that would lead to cancer going undiagnosed."

The report explores the use of a statistical calculation known as the Negative Likelihood Ratio (NLR). It shows how NLR can be calculated from a diagnostic test's sensitivity and specificity and also show the NLRs of some currently available diagnostic imaging modalities. It outlines how the BI-RADS 4A sub-category has low enough and narrow enough range of pre-test probabilities (see Table 1) to allow downgrading to a post-test probability of 2 percent or less after a negative diagnostic imaging test with an adequately low NLR.

 

FINAL ASSESSMENT CATEGORIES

Category

Management

Likelihood of cancer

0

Need Additional Imaging or Prior Examinations

Recall for Additional Imaging and/or Await Prior Examinations

n/a

1

Negative

Routine Screening

Essentially 0%

2

Benign

Routing Screening

Essentially 0%

3

Probably Benign

Short Interval Follow-up (6 month) or Continued

>0% but < 2%

4

Suspicious

Tissue Diagnosis

  • 4a. low suspicion for malignancy (>2% to < 10%)
  • 4b. moderate suspicion for malignancy (>10% to < 50%)
  • 4c. high suspicion for malignancy (>50% to <95%)

5

Highly Suggestive of Malignancy

Tissue Diagnosis

>95%

6

Known Biopsy-Proven

Surgical Excision when Clinically Appropriate

n/a

Table 1. BI-RADS Categories

Source: http://www.radiologyassistant.nl/data/bin/a53b4293920e94_TAB-Birads

"Reducing the number of unnecessary breast biopsies is an essential advancement toward improving women's healthcare and protecting breast health," said Pam Otto, M.D., Department of Radiology, The University of Texas Health Science Center at San Antonio and co-author. "I would encourage breast imagers to consider using BI-RADS 4 subcategories and NLR as important tools for helping them minimize false positive studies with minimum adverse effect on sensitivity, optimizing their patients' breast health. The availability of web-based programs for automating the NLR calculations should help to facilitate routine use of this important statistical tool."

For more information: www.ajronline.org

References

1. Yang WT, Parikh JR, Stavros AT, Otto P and Maislin G. Exploring the Negative Likelihood Ratio and How It Can Be Used to Minimize False-Positives in Breast Imaging. AJR 2018;210:301-306.

 

 

Related Content

FDA Clears iCAD's ProFound AI for Digital Breast Tomosynthesis
Technology | Mammography | December 07, 2018
iCAD Inc. announced clearance by the U.S. Food and Drug Administration (FDA) for their latest, deep-learning, cancer...
Fujifilm Collaborates With Lunit on AI Pilot Project
News | Artificial Intelligence | December 05, 2018
Fujifilm Medical Systems USA Inc. announced a joint collaboration with Korean-based medical artificial intelligence (AI...
ScreenPoint Medical and Volpara Partner to Bring AI to Breast Imaging Clinics
News | Computer-Aided Detection Software | December 04, 2018
ScreenPoint Medical has signed a memorandum of understanding (MOU) with Volpara Health Technologies. Volpara will...
GE Healthcare Introduces Invenia ABUS 2.0
Technology | Ultrasound Women's Health | December 03, 2018
GE Healthcare recently launched the Invenia automated breast ultrasound (ABUS) 2.0 system in the United States. This...
Snoring Poses Greater Cardiac Risk to Women
News | Women's Health | November 29, 2018
Obstructive sleep apnea (OSA) and snoring may lead to earlier impairment of cardiac function in women than in men,...
ScreenPoint Medical Receives FDA Clearance for Transpara Mammography AI Solution
Technology | Computer-Aided Detection Software | November 28, 2018
November 28, 2018 — ScreenPoint Medical announced it has received 510(k) clearance from the U.S.
Women Benefit From Mammography Screening Beyond Age 75
News | Mammography | November 26, 2018
Women age 75 years and older should continue to get screening mammograms because of the comparatively high incidence of...
Arterys Demonstrates AI Cloud-Based Medical Image Analysis Solutions at RSNA 2018
News | Computer-Aided Detection Software | November 26, 2018
Medical imaging software company Arterys will demonstrate its wide-ranging suite of artificial intelligence (AI)-...
Novarad Debuts NovaMG-Pro Mammography Software at RSNA 2018
News | Mammography Reporting Software | November 25, 2018
Novarad Corp. announced new mammography software NovaMG-Pro, specifically for multimodality radiologists that read...
Volpara Solutions Showcases Latest VolparaEnterprise Software Tools at RSNA
News | Mammography | November 21, 2018
Volpara Solutions Inc. will showcase its latest artificial intelligence (AI) updates at the 104th Annual Radiological...